Preparation method and application of dual-drug-loading dual-targeting nano-drug delivery system

By designing a dual-load drug dual-targeted nanodrug delivery system, using PLGA-b-mPEG and Nephrin targeted antibodies to achieve simultaneous targeted delivery of glomerulus and renal tubules, the limited effect of treatment of CKD in the prior art is solved. The problem of this paper realizes the synergistic effect of drugs and efficient renal targeting, providing a more effective treatment plan.

CN119033952APending Publication Date: 2024-11-29NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410836401.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-26
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing single-target and single-drug treatment strategies have limited effectiveness in managing CKD, and cannot fully cope with complex pathophysiological processes. The nano-drug delivery system mostly focuses on a single drug or a single targeted site, and cannot handle multiple pathological links at the same time. .

Method used

Design a dual-load drug dual-targeted nanodrug delivery system that combines hydrophobicity and Hydrophilic drugs achieve simultaneous targeted delivery of glomerulus and tubules, and use the plasmon spherical nanostructure of PLGA-b-mPEG to achieve sustained release effect.

Benefits of technology

The synergistic effect of drugs is achieved, the dosage of drugs is reduced, the treatment effect is improved, the side effects on other organs are reduced, the targeting of kidneys and drug utilization is significantly improved, and a more effective treatment plan for CKD is provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004913285980000011
    Figure HDA0004913285980000011
  • Figure HDA0004913285980000021
    Figure HDA0004913285980000021
  • Figure HDA0004913285980000022
    Figure HDA0004913285980000022
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, discloses a preparation method and application of a dual-drug-loading and dual-targeting nano-drug delivery system, and particularly discloses a dual-drug-loading and dual-targeting nano-drug delivery system which comprises poly (D, S-bis (4, 4-difluorophenyl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)-1, 2, 4-triazole-4-yl)- The medicine comprises a D, L-lactic acid-co-glycollic acid (D, L-lactic acid-co-glycollic acid)-methoxy polyethylene glycol amine copolymer, a Nephrin targeting antibody modified on the surface of the copolymer, a hydrophobic medicine coated in the (D, L-lactic acid-co-glycollic acid)-methoxy polyethylene glycol amine copolymer and a hydrophilic medicine modified on the surface of the antibody. The dual-drug-loading dual-targeting nano-drug delivery system provided by the invention can load two different drugs at the same time to synergistically treat specific diseases, shows good biocompatibility through a packaging strategy, and effectively reduces the toxicity of drugs such as TP and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a preparation method and application of a dual-drug-loaded dual-targeted nano drug delivery system (Dual-Nanodrug-System). Background Art

[0002] Currently, single-target, single-drug treatment strategies have limitations in the management of CKD, and are often ineffective because they cannot fully address complex pathophysiological processes. Therefore, it is particularly important to develop new therapies that can comprehensively intervene in multiple pathological links of CKD. Currently, nanodrug delivery systems focus on the delivery of a single drug or a single targeted site. However, most primary diseases, especially kidney diseases, often involve the simultaneous destruction of multiple different substructures, which are in a vicious cycle. Therefore, designing a nanodrug delivery system that can simultaneously load multiple drugs and deliver them to multiple sites is expected to solve the practical pain points of current nanodrug delivery systems. Summary of the invention

[0003] The present invention aims to propose a dual-target, dual-drug-loaded nanocarrier drug delivery system, which can achieve precise drug delivery by simultaneously targeting glomerular and tubular cells, further reduce the dosage of medication, give full play to the synergistic effect of drugs, and have a good sustained-release effect, in order to provide a more effective CKD treatment plan than traditional methods.

[0004] The purpose of the first aspect of the present invention is to provide a dual-drug-loaded and dual-targeted nano drug delivery system.

[0005] The purpose of the second aspect of the present invention is to provide a method for preparing the dual-drug-loaded and dual-targeted nano drug delivery system of the first aspect of the present invention.

[0006] The purpose of the third aspect of the present invention is to provide the use of the dual-drug-loaded dual-targeted nano drug delivery system of the first aspect of the present invention in the preparation of drugs for treating or preventing kidney diseases or in the preparation of drug delivery systems.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is:

[0008] The first aspect of the present invention provides a dual-drug loading and dual-targeting nano drug delivery system, comprising a poly (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer, a Nephrin targeting antibody modified on the surface of the copolymer, a hydrophobic drug encapsulated in the (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer, and a hydrophilic drug modified on the surface of the antibody.

[0009] The amphiphilic spherical nanostructure of poly (D, L-lactic acid-co-glycolic acid)-methoxypolyethylene glycol amine copolymer (PLGA-b-mPEG) can also enable the nanosystem to be slowly released locally in the kidney, achieving a sustained-release effect.

[0010] In some embodiments of the present invention, the hydrophilic drug is modified on the surface of the Nephrin targeting antibody by coupling.

[0011] In some embodiments of the present invention, the hydrophobic drug is physically embedded in the (D,L-lactic acid-co-glycolic acid)-methoxypolyethylene glycolamine copolymer.

[0012] In some embodiments of the present invention, the nephrin targeting antibody is coupled to the copolymer surface via XX reaction.

[0013] In some embodiments of the present invention, the poly(D,L-lactic acid-co-glycolic acid)-methoxypolyethylene glycolamine copolymer contains polylactic acid, EDC and methoxypolyethylene glycolamine.

[0014] In some embodiments of the present invention, the mass ratio of the polylactic acid, EDC and methoxypolyethylene glycol amine is 8-20:1:2-6.

[0015] In some preferred embodiments of the present invention, the mass ratio of the polylactic acid, EDC and methoxypolyethylene glycol amine is 10-20:1:1-4.

[0016] In some embodiments of the present invention, the preparation method of the poly (D, L-lactic acid-co-glycolic acid) -methoxy polyethylene glycol amine copolymer is as follows: polylactic acid, methoxy polyethylene glycol amine and EDC are dissolved in anhydrous chloroform, and an amide reaction is carried out under the action of a catalyst to obtain a poly (D, L-lactic acid-co-glycolic acid) -methoxy polyethylene glycol amine copolymer.

[0017] In some preferred embodiments of the present invention, the catalyst is an organotin catalyst.

[0018] In some more preferred embodiments of the present invention, the catalyst is selected from Sn(Oct)2.

[0019] In some preferred embodiments of the present invention, the reaction is carried out under stirring for 10 to 20 hours.

[0020] In some preferred embodiments of the present invention, after the amide reaction is completed, a diethyl ether / methanol mixture is used to precipitate the product.

[0021] In some embodiments of the present invention, the hydrophobic drug is selected from at least one of gefitinib, triptolide and celastrol.

[0022] In some embodiments of the present invention, the hydrophilic drug is selected from at least one of captopril, captopril acetate, dexamethasone acid, and glutathione.

[0023] The invention loads hydrophobic drugs gefitinib / tripterygium wilfordii extract into the amphiphilic block copolymer PLGA-b-mPEG, couples hydrophilic drugs captopril acetate, dexamethasone acid, and glutathione into the targeting antibody Nephrin, and finally rivets Nephrin to the surface of the nanopolymer. With the help of the spherical structure of PLGA-b-mPE and the size effect of nanoparticles, the effect of simultaneous fixed-point release of gefitinib and captopril is achieved, thereby achieving synergistic treatment, enhancing the efficacy of drugs, and reducing the toxic effects of the drugs themselves on other organs of the body.

[0024] Gefitinib and triptolide themselves have powerful anti-inflammatory effects. The sustained-release effect of contact with nanomaterials can stably exert their sustained-release properties at the lesion site. Combined with the synergistic effects of captopril acetate, dexamethasone acid, glutathione, etc., the nanosystem can obtain more powerful therapeutic capabilities and further reduce the dosage of drugs, ultimately achieving targeted treatment of acute kidney injury.

[0025] The second aspect of the present invention provides a method for preparing the dual-drug-loaded dual-targeted nano drug delivery system of the first aspect of the present invention, comprising the following steps:

[0026] Preparation of hydrophobic drug-MNPs: Mix an acetonitrile solution of a hydrophobic drug with an acetonitrile solution of a poly(D,L-lactic acid-co-glycolic acid)-methoxypolyethylene glycol amine copolymer, and add the mixture dropwise to a poloxamer 188 aqueous solution to react and obtain hydrophobic drug-MNPs;

[0027] Preparation of hydrophilic drug-Nephrin: activating the reactive groups of hydrophilic drug, Nephrin antibody and GFLG by EDC, NHS and NH2-PEG-NH2 respectively to obtain hydrophilic drug solution, Nephrin antibody solution and GFLG solution; mixing the hydrophilic drug solution with the GFLG solution, reacting and mixing with the Nephrin antibody solution, reacting to obtain hydrophilic drug-Nephrin;

[0028] Preparation of dual-drug-loaded dual-targeted nano-drug delivery system: Use EDC, NHS and NH2-PEG-NH2 to activate the reactive groups of hydrophobic drug-MNPs, adjust the pH value, and mix and react with the hydrophilic drug-Nephrin to obtain a dual-drug-loaded dual-targeted nano-drug delivery system.

[0029] In some embodiments of the present invention, in the preparation of the hydrophilic drug-Nephrin, the reaction conditions after the hydrophilic drug solution and the GFLG solution are mixed are oscillating reaction for 10 to 16 hours.

[0030] In some preferred embodiments of the present invention, the reaction conditions after the hydrophilic drug solution and the GFLG solution are mixed are oscillating reaction for 12 to 16 hours.

[0031] In some embodiments of the present invention, the reaction conditions of mixing with the Nephrin antibody solution are ultrasonication for 8 to 15 minutes and then stirring for 10 to 16 hours.

[0032] In some preferred embodiments of the present invention, the reaction conditions of mixing with the Nephrin antibody solution are ultrasonication for 8 to 12 minutes followed by stirring for 12 to 16 hours.

[0033] In some embodiments of the present invention, in the preparation of the dual-drug-loaded and dual-targeted nano-drug delivery system, the pH value is adjusted to 6.8-7.2.

[0034] In some preferred embodiments of the present invention, in the preparation of the dual-drug-loaded and dual-targeted nano drug delivery system, the pH value is adjusted to 6.8-7.0.

[0035] In some preferred embodiments of the present invention, in the preparation of the dual-drug-loaded and dual-targeted nano drug delivery system, the reaction conditions are room temperature for 2 to 3 hours.

[0036] In some embodiments of the present invention, the concentration of Nephrin is 0.1-0.5 mg / mL, preferably 0.3 mg / mL.

[0037] In some embodiments of the present invention, when the hydrophobic drug is gefitinib, the concentration of the drug is 1 to 3 mg / mL, preferably 2 mg / mL; when the hydrophobic drug is triptolide, the concentration of the drug is 1 to 10 mg / mL, preferably 10 mg / mL.

[0038] In some embodiments of the present invention, when the hydrophilic drug is captopril, the concentration of the drug is 10-40 mg / mL, preferably 35 mg / mL.

[0039] In some embodiments of the present invention, when the hydrophilic drug is dexamethasone acid, the concentration of the drug is 10 to 60 mg / mL, preferably 60 mg / mL.

[0040] In some embodiments of the present invention, when the hydrophilic drug is glutathione, the concentration of the drug is 100-200 mg / mL, preferably 200 mg / mL.

[0041] The third aspect of the present invention provides the use of the dual-drug-loaded dual-targeted nano drug delivery system of the first aspect of the present invention in the preparation of drugs for treating or preventing kidney diseases or in the preparation of drug delivery systems.

[0042] In some embodiments of the present invention, the kidney disease includes chronic kidney disease, acute kidney injury and renal cancer.

[0043] The beneficial effects of the present invention are:

[0044] The dual-drug-loaded dual-targeted nano drug delivery system provided by the present invention uses the amphiphilic polymer PLGA-b-mPEG as an assembly unit, combines nanoprecipitation and antibody-drug conjugate modification methods, and prepares a nano delivery system that can simultaneously load two different drugs for synergistic treatment of specific diseases. Through the encapsulation strategy, the dual-drug-loaded dual-targeted nano drug delivery system exhibits good biocompatibility and effectively reduces TP toxicity; the dual-drug-loaded dual-targeted nano drug delivery system has significant kidney targeting and a long kidney retention time (7d), which is beneficial to improving the utilization rate of the drug and lays a foundation for it to be used as a nano drug delivery system for the treatment of different kidney diseases.

[0045] The dual-drug-loaded dual-targeted nano drug delivery system provided by the present invention has the characteristics of simple preparation method, stable loaded drug, clear targeting properties, etc. Through size control, nano-microspheres of various sizes can be prepared very easily, and in combination with different antibodies or aptamers, the targeted carrier can even easily achieve hierarchical targeting of different organs, and is expected to realize the hierarchical targeting and intervention function of nano-carriers for intracranial vascular lesions, providing a new direction and idea for clinical targeted therapy.

[0046] Compared with a single drug loading system, a dual drug loading platform can further reduce the drug dosage concentration, and reducing the drug dosage concentration means a widening of the therapeutic dose window, which also means an increase in treatment safety. In addition, the Dual-Nanodrug-System provided by the present invention has extremely strong matching flexibility, and the two drugs loaded on the platform are flexible, which can meet various synergistic drug use needs, and different drug combinations are loaded in the dual drug loading system. Whether it is the treatment of chronic kidney disease models, acute kidney injury models or renal cancer models, the addition of synergistic drugs has greatly improved the dosage of the drugs compared to single drug loading. This drug combination can have a good therapeutic effect not only on kidney diseases, but also on a variety of primary and secondary diseases of biological organisms.

[0047] Compared with the traditional single-target, single-drug strategy, the Dual-Nanodrug-System provided by the present invention has significant advantages. First, by simultaneously targeting multiple pathological targets such as glomeruli and renal tubules, the complex pathological process of CKD can be intervened more comprehensively; second, the dual-drug system is expected to reduce the dosage of drugs while improving the therapeutic effect through synergistic effects, so as to reduce the drug exposure level in the patient's body and reduce adverse reactions. In addition, the system can minimize side effects on other organs and improve treatment safety by increasing the specific concentration of drugs in the kidneys. Therefore, the successful implementation of this study is expected to have a profound positive impact on the global CKD disease burden, reduce the medical and social costs caused by CKD, improve patients' prognosis and quality of life, and bring new treatment concepts to the global public health system. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 Schematic diagram of drug loading (a), drug release (b) and drug targeting pathway in vivo (c) of the Dual-Nanodrug-System.

[0049] Figure 2 The figures are scanning electron micrographs and elemental analysis diagrams of the Dual-Nanodrug-System and single drug-loaded nanoparticles; Figures a, b, and c are scanning electron micrographs of nanoparticles MNPs-TP loaded with triptolide (Figure a), nanoparticles MNPs-Ab-Cap loaded with antibodies and captopril (Figure b), and the Dual-Nanodrug-System (Figure c), respectively; Figure d is an elemental analysis diagram of carbon (Figure d2), oxygen (Figure d3), phosphorus (Figure d4), sulfur (Figure d5), and the four-element merge (Figure d1) in the Dual-Nanodrug-System; Figure e is an elemental analysis diagram of carbon (Figure e2), oxygen (Figure e3), and the two-element merge (Figure e1) in the MNPs skeleton.

[0050] Figure 3 Figure 2 shows the stability and release curves of single drug-loaded nanoparticles and Dual-Nanodrug-System in different media; a is the stability curve of MNPs in different media, b is the stability curve of Dual-Nanodrug-System in different media, c is the drug release curve of TP in Dual-Nanodrug-System in different solution environments, and d is the drug release curve of Cap in Dual-Nanodrug-System in different solution environments.

[0051] Figure 4Comparison of the toxicity reduction effects of free drugs and drug-encapsulated nanoparticles on cells; Figure a shows HE staining sections of the heart, liver, spleen, and lungs of mice injected with normal saline and Dual-Nanodrug-System, respectively, 21 days later; Figure b shows HE staining of testicular tissue of mice injected with normal saline, triptolide at a dose equal to the material, captopril at a dose equal to the material, and Dual-Nanodrug-System, from left to right.

[0052] Figure 5 Fluorescence imaging of in vitro organs of mice 12, 24, 48 and 72 hours after intravenous injection of free Cy7 (a) and Cy7-Dual-Nanodrug-System (b) (50 mg / kg). In the figure, 1 to 9 represent the heart, liver, spleen, lung, kidney, thymus, small intestine, muscle and brain, respectively.

[0053] Figure 6 Comparison of the improvement of podocytes in the kidneys of mice with puromycin nephropathy model under transmission electron microscopy before and after treatment with single-drug and Dual-Nanodrug-System.

[0054] Figure 7 Comparison of the therapeutic effects of Dual-Nanodrug-System on different disease models after changing different drug combinations in acute kidney injury model and chronic renal carcinoma in situ model; wherein, a is the kidney pathological staining of mice in different treatment groups after treatment in acute kidney injury model (AKI) mice; b and c are the improvements in urea nitrogen (b) and creatinine (c) of AKI mice after treatment with different treatment regimens; Figure d is a schematic diagram of the experimental process; Figure e is a luminescence image of tumor cells in mice in different treatment groups after treatment in renal carcinoma in situ model (RCCCs); f is a schematic diagram of liver metastasis of renal cancer cells; g is a gross view of cancer foci in the kidney and liver in each group of renal cancer models; h is the change in the survival curve of each group of mice during the treatment cycle. DETAILED DESCRIPTION

[0055] The present invention is further described in detail below through specific examples.

[0056] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0057] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0058] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0059] Example 1

[0060] A dual-drug-system (MNPs-TP-Cap) for dual drug delivery includes PLGA-b-mPEG, an antibody-captopril (Cap) conjugate Cap-Nephrin modified on the surface of an antibody, and a hydrophobic drug 1 triptolide (TP) loaded in the inner core of the PLGA-b-mPEG.

[0061] The preparation method of the above-mentioned dual-drug-loaded dual-targeted nano drug delivery system is as follows: the hydrophobic drug 1 triptolide (TP) is combined with the amphiphilic block copolymer PLGA-b-mPEG by double emulsification combined with activated antibody-drug coupling method, and TP is physically coated inside to prepare TP-MNPs; the reactive groups are activated by EDC, NHS and NH2-PEG-NH2 and reacted under ultrasound to prepare antibody-drug conjugate Cap-Nephrin; finally, TP-MNPs are activated by EDC and NHS, and Cap-Nephrin is added after adjusting the pH to obtain a dual-drug-loaded dual-targeted nano drug delivery system. Its preparation process is as follows Figure 1 As shown in A.

[0062] Specifically, the preparation method of the dual-drug-loaded dual-targeted nano drug delivery system comprises the following steps:

[0063] (1) Preparation of amphiphilic block copolymer PLGA-b-mPEG

[0064] PLGA (1 g), mPEG-NH (250 mg) and EDC (75 mg) were dissolved in 5 mL of anhydrous chloroform and stirred vigorously at room temperature for 12 h. After the reaction, 15 mL of ether / methanol mixture (v / v, 1:1, 0°C) was added to precipitate the product, and the lower layer residue was collected by centrifugation (10000 rpm, 15 min). The upper layer liquid was rotary evaporated to remove the solvent. Then, all the residues were dissolved in a small amount of acetonitrile, and the product was precipitated with ether / methanol (v / v, 1:5, 0°C). The product was collected by centrifugation (10000 rpm, 15 min), and the dissolution-precipitation was repeated 3 times to purify the product. Finally, the product was vacuum dried at 35°C to constant weight to obtain a brown solid, i.e., PLGA-b-mPEG, which was stored at -20°C for future use.

[0065] (2) Preparation of TP-MNPs

[0066] Under vigorous stirring, 2 mL of PLGA-b-mPEG acetonitrile solution (100 mg / mL) was added dropwise to 2 mL of poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times. When preparing TP-MNPs or Cy7-TP-MNPs, TP or Cy7 and PLGA-b-mPEG were first dissolved in acetonitrile, and then TP-MNPs or Cy7-TP-MNPs were prepared according to the preparation and purification method of MNPs.

[0067] (3) Preparation of Cap-Nephrin

[0068] Nephrin antibody (Abcam, UK, ab216341) was diluted at a ratio of 1:100 and ultrasonically treated for 10 min to be dispersed in 5 mL of phosphate buffer (PB, 10 mM, pH 5.8). Subsequently, EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto and stirred at room temperature for 3 h to activate the carboxyl groups on its surface to obtain Nephrin-NHS. The obtained Nephrin-NHS was resuspended in PB (5 mL, 10 mM, pH 7.4) to obtain a Nephrin dispersion for later use.

[0069] The Gly-Phe-Leu-Gly (GFLG) tetrapeptide linker stock solution was diluted 1:50, dispersed in PBS (pH 7.4), and EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto for reaction for 9 hours to obtain an activated GFLG dispersion for later use.

[0070] Take 10 ml of 50 mg / mL Cap solution, add EDC (50 mg / mL) and NHS (5 mg / mL) to react for 9 hours, then add 5 mL NH2-PEG-NH2 (10 mM) to the above reactants, blow dry the obtained sample with N2, add the obtained concentrated product to the GFLG dispersion, shake for 12 hours, blow dry the obtained sample with N2 again, add the concentrated product to the Nephrin dispersion, and ultrasonicate the mixture for 10 minutes. Finally, the above mixture was stirred at room temperature for overnight reaction (12 hours), and then the prepared Cap-Nephrin was collected by centrifugation (10000 rpm, 10 minutes, 4°C), and the sample was washed three times with ultrapure water (5 mL). The obtained Cap-Nephrin was then lyophilized and stored at -20°C.

[0071] (4) Preparation of dual-drug-loaded and dual-targeted nanodrug delivery system

[0072] TP-MNPs were dissolved in PB (5 mL, 10 mM, pH 6.0). 100 μL of 200 mM EDC and NHS (5 mg / mL) were added to PB (5 mL, 10 mM, pH 7.4) to prepare an activation solution to be used. TP-MNPs were mixed with the above-prepared activation solution and stirred for 15 min, and then the excess EDC and EDC byproducts were removed using a Zeba TM desalting spin column. The pH value of the activated TP-MNPs solution was adjusted to 7.0, 100 μL of Cap-Nephrin was added, and the reaction was carried out at room temperature for 2 h, and then the product was collected and washed three times by centrifugation with PBS (pH 7.4). The final product (i.e., Dual-Nanodrug-System) was stored at -20 °C.

[0073] Example 2

[0074] A dual-drug-loaded dual-targeted nano drug delivery system (MNPs-Cap-TP) comprises PLGA-b-mPEG, antibody-captopril conjugate Cap-Nephrin modified on the antibody surface, and TP loaded in the PLGA-b-mPEG core.

[0075] The preparation method of the dual-drug-loaded dual-targeted nano drug delivery system is as follows: the hydrophobic drug 1 triptolide (TP) is combined with the amphiphilic block copolymer PLGA-b-mPEG by a double emulsification combined with an activated antibody-drug conjugate method, and TP is physically coated inside to prepare TP-MNPs, and then the reactive groups are activated by EDC, NHS and NH2-PEG-NH2 and reacted under ultrasound to prepare the antibody-drug conjugate Cap-Nephrin; finally, TP-MNPs are activated by EDC and NHS, and Cap-Nephrin is added after adjusting the pH. The preparation process is as follows: Figure 1 As shown in A.

[0076] Specifically, the preparation method of the dual-drug-loaded dual-targeted nano drug delivery system comprises the following steps:

[0077] (1) Preparation of amphiphilic block copolymer PLGA-b-mPEG

[0078] PLGA (1 g), mPEG-NH (250 mg) and EDC (75 mg) were dissolved in 5 mL of anhydrous chloroform and stirred vigorously at room temperature for 16 h. After the reaction, 15 mL of ether / methanol mixture (v / v, 1:1, 0°C) was added to precipitate the product, and the lower layer residue was collected by centrifugation (10000 rpm, 15 min). The upper layer liquid was rotary evaporated to remove the solvent. Then, all the residues were dissolved in a small amount of acetonitrile, and the product was precipitated with ether / methanol (v / v, 1:5, 0°C). The product was collected by centrifugation (10000 rpm, 15 min), and the dissolution-precipitation was repeated 3 times to purify the product. Finally, the product was vacuum dried at 35°C to constant weight to obtain a brown solid, i.e., PLGA-b-mPEG, which was stored at -20°C for future use.

[0079] (2) Preparation of TP-MNPs

[0080] Under vigorous stirring, 2 mL of PLGA-b-mPEG acetonitrile solution (100 mg / mL) was added dropwise to 2 mL of poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times. When preparing TP-MNPs or Cy7-TP-MNPs, TP or Cy7 and PLGA-b-mPEG were first dissolved in acetonitrile, and then TP-MNPs or Cy7-TP-MNPs were prepared according to the preparation and purification method of MNPs (same as Comparative Example 1).

[0081] (3) Preparation of Cap-Nephrin

[0082] Nephrin antibody was diluted at a ratio of 1:100 and ultrasonically treated for 10 min to be dispersed in 5 mL of phosphate buffer (PB, 10 mM, pH 5.8). Subsequently, EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto and stirred at room temperature for 3 h to activate the carboxyl groups on its surface to obtain Nephrin-NHS. The obtained Nephrin-NHS was resuspended in PB (5 mL, 10 mM, pH 7.4) to obtain a Nephrin dispersion for later use.

[0083] GFLG was diluted 1:50 and dispersed in PBS (pH 7.4), and EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto for reaction for 10 h to obtain an activated GFLG dispersion for later use.

[0084] EDC (50 mg / mL) and NHS (5 mg / mL) were added to the 50 mg / mL Cap solution and reacted for 10 h. Subsequently, 5 mL NH2-PEG-NH2 (10 mM) was added to the above reactants, the obtained sample was blown dry with N2, the obtained concentrated product was added to the GFLG dispersion, the shaker was reacted for 16 h, the obtained sample was blown dry with N2 again, the concentrated product was added to the Nephrin dispersion, and the mixture was ultrasonicated for 10 min. Finally, the above mixture was stirred at room temperature for overnight reaction (16 h), and then the prepared Cap-Nephrin was collected by centrifugation (10000 rpm, 10 min, 4 ° C), and the sample was washed three times with ultrapure water (5 mL). The obtained Cap-Nephrin was then lyophilized and stored at -20 ° C.

[0085] (4) Preparation of dual-drug-loaded and dual-targeted nanodrug delivery system

[0086] TP-MNPs were dissolved in PB (5 mL, 10 mM, pH 6.0). 100 μL of 200 mM EDC and NHS (5 mg / mL) were added to PB (5 mL, 10 mM, pH 7.4) to prepare an activation solution to be used. TP-MNPs were mixed with the above-prepared activation solution and stirred for 15 min, and then the excess EDC and EDC byproducts were removed using a Zeba TM desalting spin column. The pH value of the activated TP-MNPs solution was adjusted to 7.0, 100 μL of Cap-Nephrin was added, and the reaction was carried out at room temperature for 3 h, and then the product was collected and washed three times by centrifugation with PBS (pH 7.4). The final product (i.e., Dual-Nanodrug-System) was stored at -20 °C.

[0087] Example 3

[0088] A dual-drug-loaded dual-targeted nano drug delivery system (Dex-MNPs-TP) includes PLGA-b-mPEG, antibody-dexamethasone acetate (Dex) conjugate Dex-Nephrin modified on the antibody surface, and hydrophobic drug 1 triptolide (TP) loaded in the PLGA-b-mPEG core.

[0089] The dual-drug-loading dual-targeted nano drug delivery system combines the hydrophobic drug 1 triptolide (TP) with the amphiphilic block copolymer PLGA-b-mPEG through a double emulsification combined with an activated antibody-drug conjugate method, and physically encapsulates TP inside to prepare TP-MNPs; then, the reactive groups are activated by EDC, NHS and NH2-PEG-NH2 and reacted under ultrasound to prepare the antibody-dexamethasone acetate conjugate Dex-Nephrin; finally, TP-MNPs are activated by EDC and NHS, and Dex-Nephrin is added after adjusting the pH. The preparation process is as follows: Figure 1 As shown in A.

[0090] Specifically, the preparation method of the dual-drug-loaded dual-targeted nano drug delivery system comprises the following steps:

[0091] (1) Preparation of amphiphilic block copolymer PLGA-b-mPEG

[0092] PLGA (1 g), mPEG-NH (250 mg) and EDC (75 mg) were dissolved in 5 mL of anhydrous chloroform and stirred vigorously at room temperature for 12 h. After the reaction, 15 mL of ether / methanol mixture (v / v, 1:1, 0°C) was added to precipitate the product, and the lower layer residue was collected by centrifugation (10000 rpm, 15 min). The upper layer liquid was rotary evaporated to remove the solvent. Then, all the residues were dissolved in a small amount of acetonitrile, and the product was precipitated with ether / methanol (v / v, 1:5, 0°C). The product was collected by centrifugation (10000 rpm, 15 min), and the dissolution-precipitation was repeated 3 times to purify the product. Finally, the product was vacuum dried at 35°C to constant weight to obtain a brown solid, i.e., PLGA-b-mPEG, which was stored at -20°C for future use.

[0093] (2) Preparation of TP-MNPs

[0094] Under vigorous stirring, 2 mL of PLGA-b-mPEG acetonitrile solution (100 mg / mL) was added dropwise to 2 mL of poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times. When preparing TP-MNPs or Cy7-TP-MNPs, TP or Cy7 and PLGA-b-mPEG were first dissolved in acetonitrile, and then TP-MNPs or Cy7-TP-MNPs were prepared according to the preparation and purification method of MNPs (same as Example 1).

[0095] (3) Preparation of Dex-Nephrin

[0096] Nephrin antibody was diluted at a ratio of 1:100 and ultrasonically treated for 10 min to be dispersed in 5 mL of phosphate buffer (PB, 10 mM, pH 5.8). Subsequently, EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto and stirred at room temperature for 3 h to activate the carboxyl groups on its surface to obtain Nephrin-NHS. The obtained Nephrin-NHS was resuspended in PB (5 mL, 10 mM, pH 7.4) to obtain a Nephrin dispersion for later use.

[0097] GFLG was diluted 1:50 and dispersed in PBS (pH 7.4), and EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto to react for 9 hours to obtain an activated GFLG dispersion for later use.

[0098] EDC (50 mg / mL) and NHS (5 mg / mL) were added to the 60 mg / mL Dex solution and reacted for 9 h. Subsequently, 5 mL NH2-PEG-NH2 (10 mM) was added to the above reactants, the obtained sample was blown dry with N2, the obtained concentrated product was added to the GFLG dispersion, the shaker was reacted for 12 h, the obtained sample was blown dry with N2 again, the concentrated product was added to the Nephrin dispersion, and the mixture was ultrasonicated for 10 min. Finally, the above mixture was stirred at room temperature for overnight reaction (12 h), and then the prepared Dex-Nephrin was collected by centrifugation (10000 rpm, 10 min, 4 ° C), and the sample was washed three times with ultrapure water (5 mL). The obtained Dex-Nephrin was then lyophilized and stored at -20 ° C.

[0099] (4) Preparation of dual-drug-loaded and dual-targeted nanodrug delivery system

[0100] TP-MNPs were dissolved in PB (5 mL, 10 mM, pH 6.0). 100 μL of 200 mM EDC and NHS (5 mg / mL) were added to PB (5 mL, 10 mM, pH 7.4) to prepare an activation solution to be used. TP-MNPs were mixed with the above-prepared activation solution and stirred for 15 min, and then the excess EDC and EDC byproducts were removed using a Zeba TM desalting spin column. The pH value of the activated TP-MNPs solution was adjusted to 7.0, 100 μL of Dex-Nephrin was added, and the reaction was carried out at room temperature for 2 h. The product was then collected and washed three times by centrifugation with PBS (pH 7.4). The final product (i.e., Dual-Nanodrug-System) was stored at -20 °C.

[0101] Example 4

[0102] A dual-drug-loaded dual-targeted nano drug delivery system (GSH-MNPs-Gef) includes PLGA-b-mPEG, antibody-glutathione (Glutataione, GSH) conjugate GSH-Nephrin modified on the antibody surface, and hydrophobic drug 1 gefitinib (Gef) loaded in the PLGA-b-mPEG core.

[0103] The dual-drug-loading dual-targeted nano drug delivery system combines the hydrophobic drug 1 gefitinib (Gef) with the amphiphilic block copolymer PLGA-b-mPEG through a double emulsification combined with an activated antibody-drug conjugate method, and Gef is physically coated inside to prepare Gef-MNPs; then the reactive groups are activated by EDC, NHS and NH2-PEG-NH2 and reacted under ultrasound to prepare the antibody-glutathione conjugate GSH-Nephrin; finally, Gef-MNPs are activated by EDC and NHS, and GSH-Nephrin is added after adjusting the pH. The preparation process is as follows: Figure 1 As shown in A.

[0104] Specifically, the preparation method of the dual-drug-loaded dual-targeted nano drug delivery system comprises the following steps:

[0105] (1) Preparation of amphiphilic block copolymer PLGA-b-mPEG

[0106] PLGA (1 g), mPEG-NH (250 mg) and EDC (75 mg) were dissolved in 5 mL of anhydrous chloroform and stirred vigorously at room temperature for 12 h. After the reaction, 15 mL of ether / methanol mixture (v / v, 1:1, 0°C) was added to precipitate the product, and the lower layer residue was collected by centrifugation (10000 rpm, 15 min). The upper layer liquid was rotary evaporated to remove the solvent. Then, all the residues were dissolved in a small amount of acetonitrile, and the product was precipitated with ether / methanol (v / v, 1:5, 0°C). The product was collected by centrifugation (10000 rpm, 15 min), and the dissolution-precipitation was repeated 3 times to purify the product. Finally, the product was vacuum dried at 35°C to constant weight to obtain a brown solid, i.e., PLGA-b-mPEG, which was stored at -20°C for future use.

[0107] (2) Preparation of Gef-MNPs

[0108] Under vigorous stirring, 2 mL of PLGA-b-mPEG acetonitrile solution (100 mg / mL) was added dropwise to 2 mL of poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times. When preparing Gef-MNPs or Cy7-Gef-MNPs, Gef or Cy7 and PLGA-b-mPEG were first dissolved in acetonitrile, and then Gef-MNPs or Cy7-Gef-MNPs were prepared according to the preparation and purification method of MNPs (same as Comparative Example 2).

[0109] (3) Preparation of GSH-Nephrin

[0110] Nephrin antibody was diluted at a ratio of 1:100 and ultrasonically treated for 10 min to be dispersed in 5 mL of phosphate buffer (PB, 10 mM, pH 5.8). Subsequently, EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto and stirred at room temperature for 3 h to activate the carboxyl groups on its surface to obtain Nephrin-NHS. The obtained Nephrin-NHS was resuspended in PB (5 mL, 10 mM, pH 7.4) to obtain a Nephrin dispersion for later use.

[0111] GFLG was diluted 1:50 and dispersed in PBS (pH 7.4), and EDC (50 mg / mL) and NHS (5 mg / mL) were added thereto to react for 9 hours to obtain an activated GFLG dispersion for later use.

[0112] EDC (50 mg / mL) and NHS (5 mg / mL) were added to a 200 mg / mL GSH solution and reacted for 9 h, followed by adding 5 mL NH2-PEG-NH2 (10 mM) to the above reactants, blowing the obtained sample dry with N2, adding the obtained concentrated product to the GFLG dispersion, shaking for 12 h, blowing the obtained sample dry with N2 again, adding the concentrated product to the Nephrin dispersion, and ultrasonicating the mixture for 10 min. Finally, the above mixture was stirred at room temperature for overnight reaction (12 h), and then the prepared GSH-Nephrin was collected by centrifugation (10000 rpm, 10 min, 4 ° C), and the sample was washed three times with ultrapure water (5 mL). The obtained GSH-Nephrin was then lyophilized and stored at -20 ° C.

[0113] (4) Preparation of dual-drug-loaded and dual-targeted nanodrug delivery system

[0114] Gef-MNPs were dissolved in PB (5 mL, 10 mM, pH 6.0). 100 μL 200 mM EDC and NHS (5 mg / mL) were added to PB (5 mL, 10 mM, pH 7.4) to prepare an activation solution to be used. Gef-MNPs were mixed with the above-prepared activation solution and stirred for 15 min, and then the excess EDC and EDC byproducts were removed using a Zeba TM desalting spin column. The pH value of the activated Gef-MNPs solution was adjusted to 7.0, 100 μL GSH-Nephrin was added, and the reaction was carried out at room temperature for 2 h, and then the product was collected and centrifuged and washed three times with PBS (pH 7.4). The final product (i.e., Dual-Nanodrug-System) was stored at -20 °C.

[0115] Comparative Example 1

[0116] Preparation method of TP-MNPs (i.e., TP@MNPs): 0.5 mg TP was dissolved in 2 mL PLGA-b-mPEG acetonitrile solution (100 mg / mL) under vigorous stirring, and then the mixture was added dropwise to 2 mL poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the TP-MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times.

[0117] Preparation method of Cy7-MNPs-TP: Under vigorous stirring, 0.5 mg TP and 0.5 mg cy7 dye were dissolved in 2 mL PLGA-b-mPEG acetonitrile solution (100 mg / mL), and then the mixture was added dropwise to 2 mL poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, TP-MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times.

[0118] Preparation method of MNPs-mAb-Cap: MNPs were prepared according to the method described in Example 1-(1) and dissolved in PB (5 mL, 10 mM, pH 6.0). 100 μL of 200 mM EDC and NHS (5 mg / mL) were added to PB (5 mL, 10 mM, pH 7.4) to prepare an activation solution to be used. MNPs were mixed with the above-prepared activation solution and stirred for 15 min, and then the excess EDC and EDC by-products were removed using a ZebaTM desalting spin column. The pH value of the activated MNPs solution was adjusted to 7.0, and Cap-Nephrin was prepared according to the method described in Example 1-(3), and 100 μL of the Cap-Nephrin finished solution was taken and added to the activated MNPs, reacted at room temperature for 2 h, and then the product was collected and centrifuged and washed three times with PBS (pH 7.4). The final product (i.e., MNPs-mAb-Cap) was stored at -20°C.

[0119] Comparative Example 2

[0120] Preparation method of Gef-MNPs: 2 mg Gef was dissolved in 2 mL PLGA-b-mPEG acetonitrile solution (100 mg / mL) under vigorous stirring, and then the mixture was added dropwise to 2 mL poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the Gef-MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times.

[0121] Preparation method of Cy7-Gef-TP: 2 mg Gef and 0.5 mg cy7 dye were dissolved in 2 mL PLGA-b-mPEG acetonitrile solution (100 mg / mL) under vigorous stirring, and then the mixture was added dropwise to 2 mL poloxamer 188 aqueous solution (50 mg / mL) at a rate of 0.5 mL / min. When the acetonitrile was completely evaporated, the cy7-Gef-MNPs were collected by centrifugation (6600 rpm, 10 min) and washed with water three times.

[0122] Effect Example

[0123] 1. Structural characterization of dual-drug loading and dual-targeting nano drug delivery system

[0124] The dual-drug-loaded dual-targeted nano drug delivery system prepared in Examples 1 to 4 was characterized by scanning electron microscopy. The results showed that the scanning electron microscopy image of the dual-drug-loaded dual-targeted nano drug delivery system (Cap-MNPs-TP) in Example 1 was as follows: Figure 2 As shown. Figure 2It can be seen that before modification with antibodies, TP-MNPs nanoparticles present a spherical structure with a smooth surface. After modification with antibodies, the surface of the nanoparticles becomes obviously rough, which is also indirect evidence of the successful loading of Cap on the surface of MNPs. At the same time, the above three drug-loaded nanoparticles all present a size of about 400nm, which is the prerequisite for their targeting to renal proximal tubular epithelial cells. The targeting driving force is the absorption pressure of the capillaries around the renal proximal tubules on the renal interstitium.

[0125] The morphology and size of the dual-drug-loaded and dual-targeted nano drug delivery systems prepared in Examples 2 to 4 are similar to those in Example 1.

[0126] 2. Taking the Cap-MNPs-TP of Example 1 as an example, the performance of the Dual-Nanodrug-System was tested.

[0127] (1) Stability evaluation of Dual-Nanodrug-System

[0128] In order to investigate the stability of the Dual-Nanodrug-System, MNPs and the Dual-Nanodrug-System were placed in two liquids simulating the systemic circulation environment (i.e., 10% FBS and PBS (pH 7.4)) to observe their stability. 10% FBS is used to simulate the blood circulation environment, and pH 7.4 PBS is used to simulate the normal physiological environment in the body. The saline group was used as a control.

[0129] The results are as follows Figure 3 As shown in a and b, MNPs without any drug loading can maintain a size of about 400nm in various media for 5 days. After 5 days, the particle size has a clear upward trend. This is because the preparation unit of MNPs is polymer. During the storage process, the polymer is prone to agglomeration, which leads to an increase in the particle size of the nanoparticles. Compared with MNPs, Dual-Nanodrug-System has more superior stability. Its particle size changes less than 26nm within 10 days of storage. This is because the grafted GFLG polypeptide in ADC has strong stability. In addition, the loading of the Dual-Nanodrug-System layer can also avoid polymer agglomeration to a certain extent.

[0130] (2) In vitro drug release of Dual-Nanodrug-System Figure 1 b)

[0131] 10% FBS (simulating blood circulation environment), PBS (titrated with cathepsin B to a pH of 6.4) (simulating pathological environment), renal tissue homogenate (adding 2 times NS (g / ml) to the kidney and homogenizing the kidney with a cell crusher to simulate the kidney environment) and normal saline (as a control) were used as dialysate to study the release of Dual-Nanodrug-System in the above solutions over time.

[0132] The results are as follows Figure 3 As shown in c and d. Figure 3 Figures c and d are drug release curves of TP and Cap in the Dual-Nanodrug-System in different solution environments. As can be seen from the figure, in the environment of renal tissue homogenate and PBS (6.4), the release rate of TP is less than 20% within 5 hours. The release rate of Cap in the same environment can reach 60% within 5 hours. After 10 hours, the release amount of Cap reaches saturation, while the release rate of TP is still rising after 10 hours. This result shows that in the kidney environment, the release process of the two drugs is graded, that is, Cap is a sustained release of the drug, and TP is a steady sustained release. This is because Cap is exposed to the outside of the Dual-Nanodrug-System, while TP is inside the Dual-Nanodrug-System. In the simulated blood circulation and normal physiological environment, the release amount of Cap and TP is almost 0, which shows that the Dual-Nanodrug-System will not have drug off-target in the blood circulation, because the GFLG in its surface-modified ADC can only be decomposed by tissue proteases in cells, and GFLP will not be prematurely dissociated due to changes in factors such as pH in the body. This cascade response drug release process will not cause a large accumulation of both drugs in the body at the same time, which helps to exert a synergistic effect between the two drugs and avoid systemic toxicity and immunotoxicity caused by excessive drug dosage.

[0133] (3) Study on the biocompatibility and toxicity reduction effect of Dual-Nanodrug-System

[0134] The Dual-Nanodrug-System and saline were injected into mice to observe whether there were any differences between the groups of mice, and HE staining was performed on the various organs of the mice in each group. The results showed that no difference was observed between the control group injected with ADC-MNPs-TP and the control group injected with saline, proving that the material has a strong affinity for biological organisms and will not cause rejection reactions and organ toxicity. This result was supported by the HE staining results of various organs of the mice ( Figure 4 (a)

[0135] Triptolide, MNPs and Dual-Nanodrug-System were injected into mice once every 2 days for 21 days, and then the testicular tissues of mice were collected to observe the differences in reproductive toxicity of TP before and after being encapsulated by the nanosystem. Testicular staining results ( Figure 4 Middle b) shows that free TP can damage the testicular structure of mice and inhibit spermatogenesis, while after being encapsulated by MNPs, MNPs and Dual-Nanodrug-System can correct the spermatogenesis dysfunction caused by TP.

[0136] (4) Study on the kidney targeting of Dual-Nanodrug-System Figure 1 c)

[0137] The premise for nanocarriers to achieve efficient treatment is to have good organ targeting. Here, male C57BL / 6 mice were selected as experimental mice, and Cy7-labeled Dual-Nanodrug-System (i.e., the dual-drug-loading dual-targeted nanodrug delivery system formed by Cy7-TP-MNPs and Cap-Nephrin in Example 1) was administered by tail vein injection, and then the mice were sacrificed at different time points and their hearts, livers, spleens, lungs, kidneys, thymus, small intestines, muscles and brains were taken for in vitro organ fluorescence imaging.

[0138] Figure 5 The fluorescence imaging and fluorescence intensity statistics of isolated organs of mice at 0.5, 1, 2 and 3 days after drug administration. Figure 5 It can be seen that compared with the free fluorescent dye Cy7, the kidneys emit obvious fluorescence at all time points. At the same time, the fluorescence of other organs except the liver is very weak or even non-existent. This result shows that the Dual-Nanodrug-System has good kidney targeting. It is worth noting that in addition to the kidneys, the liver also shows a strong fluorescence intensity. This is because the liver is the most important metabolic and immune organ, and its main function is to identify and remove foreign substances in the body. Therefore, the Dual-Nanodrug-System will also be enriched in the liver. On this basis, the fluorescence intensity of each organ of the mouse was counted.

[0139] like Figure 5 As shown, at each time point, the fluorescence brightness of the kidney is higher than that of other organs (refer to the fluorescence intensity column on the right, from blue to red, the intensity increases). For example, 12 hours after administration, the fluorescence brightness of the kidney is significantly higher than that of other organs, which fully demonstrates that the Dual-Nanodrug-System has long-term kidney targeting performance.

[0140] (5) Study on the therapeutic effect of Dual-Nanodrug-System on puromycin nephropathy model mice

[0141] In order to explore the therapeutic effect of Dual-Nanodrug-System on puromycin nephropathy model mice, male C57BL / 6 mice were selected as experimental animals, and a puromycin nephropathy mouse model simulating focal segmental sclerosing glomerulonephritis was established by intraperitoneal injection of puromycin. The experimental mice were randomly divided into 5 groups, 5 mice in each group, and received different treatments: sham group, model + saline group, model + low-dose TP@MNPs group (TP 0.001mg / mL), model + low-dose-MNPs-mAb-5 Cap group (Cap 5mg / mL) and model + Dual-Nanodrug-System group (including TP 0.001mg / mL, Cap 5mg / mL). After a single intraperitoneal injection of 350mg / kg body weight of puromycin, various therapeutic drugs were injected into the tail vein according to the grouping, and continued for 21 days, once every other day. On the 14th day, we collected kidney samples from 5 mice sacrificed in each group and performed pathological examination on the kidney tissues, and made electron microscopic sections to observe the ultrastructural changes of podocytes.

[0142] The specific operation process is as follows: a kidney tissue block with a thickness of less than 4 μm is cut and fixed in electron microscopy specimen fixative for 24 hours. Then, it is transferred to PBS buffer and sent to the electron microscopy center for slide preparation, staining and photography.

[0143] The results are as follows Figure 6 As shown in Figure 1, the ultrastructural changes of podocytes shown in kidney electron microscopic sections at 14 days further verified the improvement of the material on podocytes. Figure 6 As shown, mice in the model group and single drug-loaded groups (i.e., TP@MNPs group and MNPs-mAb-5Cap (captopril drug loaded alone) group) showed severe fusion and shedding of podocytes, but the foot process structure in the Dual-Nanodrug-System group showed only minimal fusion.

[0144] (6) Study on the therapeutic effect of Dual-Nanodrug-System on acute kidney injury model

[0145] In order to treat acute kidney injury, through literature review and drug screening, triptolide and dexamethasone were finally selected as two drugs for the treatment of acute kidney injury. In order to further explore the difference between dual drug loading and single drug loading, a single drug loading system (i.e., a single drug loading system loaded with only one of the drugs) and a Dual-Nanodrug-System (i.e., Dex-MNPs-TP in Example 3) of the above drug combination were prepared, and the difference between the single drug loading and dual drug loading systems was further explored.

[0146] For the acute kidney injury model, male C57BL / 6 mice were selected as experimental animals. The experimental mice were randomly divided into 5 groups, 5 mice in each group, and given different treatments, including sham group, model + saline group, model + single TP module group (TP: 0.005 mg / kg body weight), model + single Dex module group (Dex: 0.05 mg / kg body weight), model + Dex-MNPs-TP module group (TP: 0.005 mg / kg body weight; Dex: 0.05 mg / kg body weight), all treatments were injected 3 days before surgery. 24 hours after surgery, all mice were anesthetized and their kidney tissues were collected for histopathological examination and analysis.

[0147] exist Figure 7 As can be seen from a to c, when the dose was reduced to 0.005 mg / kg body weight, neither MNPs-TP nor ADC(Dex)-MNPs (prepared in the same way as MNPs-TP) could improve the renal pathology and deterioration of renal function. However, ADC(Dex)-MNPs-TP showed a significant improvement, indicating that the synergistic effect of the drugs was effective.

[0148] (7) Study on the therapeutic effect of Dual-Nanodrug-System on renal carcinoma in situ model

[0149] In order to treat renal carcinoma in situ, through literature review and drug screening, gefitinib (Gef) and glutathione (GSH) were finally selected as therapeutic drugs against renal carcinoma in situ. In order to further explore the advantages of the drug-carrying system, a simple mixture of the above drug combination and a dual drug-carrying system (i.e., GSH-MNPs-Gef in Example 4) were prepared, and the difference between the simple mixture (GSH and Gef were dissolved in 0.2% 1,2-propylene glycol solution, so that the GSH concentration was 0.01 mg / mL; the Gef concentration was 0.05 mg / mL) and the dual drug-carrying system (the loading drug concentration was the same as the physical mixing concentration) was further explored.

[0150] For the renal carcinoma in situ model, male nude mice were selected as experimental animals. The specific operation was as follows:

[0151] 1) The nude mice were randomly divided into four groups: sham operation group, model group (RCCC), low-dose anticancer drug simple mixture group (GSH concentration 0.01 mg / mL; Gef concentration 0.05 mg / mL) and low-dose Dual-Nanodrug-System (same drug concentration) intervention group.

[0152] 2) Before the experiment, culture Caki-1 luciferase cells to an appropriate density according to the normal cell culture method. On the day of surgery, digest them with EDTA-free trypsin and resuspend them in HBSS buffer. Calculate the cell suspension density using a cell counter and adjust it to 4×10 4 cells / μL for later use.

[0153] 3) The mouse was anesthetized with isoflurane, and then placed in a prone position and fixed on an operating table. A 1 cm small incision was made along the left abdomen of the mouse, and the kidney was gently squeezed out from the incision.

[0154] 4) Tumor cell injection was performed using a microsyringe and a G27 flat-tip needle. The needle was inserted from the lower pole of the kidney and advanced to a point where it just reached the capsule of the upper pole of the kidney for injection.

[0155] 5) In the sham group, 0.05 ml of HBSS buffer was injected, while in the other three groups, 2 million viable Caki-1 cells were injected in 0.05 ml of HBSS. The injection was successful when the renal capsule was slightly bulged. The needle was carefully withdrawn as quickly as possible, and the animal was checked for local bleeding and leakage of tumor cell suspension.

[0156] 6) After the wound was sutured, the nude mouse was placed in a 37°C constant temperature pad and waited for awakening. After awakening, the nude mouse was returned to the cage and continued to be raised.

[0157] After in situ injection, each group of mice was injected with the corresponding drug through the tail vein every 2 days, and the mice were imaged with fluorescence every 7 days ( Figure 7 d). The specific operations are:

[0158] 1) Use sterile DPBS (w / o Mg 2+ , Ca 2+ ) Prepare 15 mg / mL luciferin stock solution and mix well.

[0159] 2) Sterilize by filtration using a 0.2 μm filter membrane.

[0160] 3) Nude mice were injected intraperitoneally (ip) at a concentration of 150 mg / kg of luciferin / body weight.

[0161] 4) 10 to 15 minutes after injection (waiting for the light signal to reach the strongest stable plateau), use a small animal imager for imaging analysis.

[0162] During the injection period, the weight changes and mortality of mice need to be continuously monitored. After 35 days of injection, all mice were observed and their liver and kidney tissues were collected.

[0163] exist Figure 7 Figures e to h show the weekly tumor luminescence of nude mice in each group. The results showed that the tumors of mice in the model group grew rapidly. Combining the weight changes and mortality rates, it can be seen that the mice in this group lost weight quickly and had the highest mortality rate. The tumors of mice in the free anticancer drug mixed group also grew rapidly, but began to shrink to a certain extent between 28 and 35 days. Their weight also began to recover after 28 days. The tumors of mice in the ADC (GSH) -MNPs -Gef group grew slowly, the mortality rate of mice was low, and the weight recovery rate was high. The results suggest that kidney-specific delivery can bring a more significant improvement in the efficacy of anti-tumor treatment.

[0164] From the liver and kidney tissues of mice in each group collected after 35 days, we can observe that the kidneys of mice in the model group are enlarged as a whole, accompanied by irregular cancerous protrusions. The kidney morphology and size of the two treatment groups have improved to a certain extent, among which ADC (GSH) -MNPs-Gef has the best effect, and only the upper pole of the kidney at the injection site has morphological changes. At the same time, the nude mice in the model group and the free drug mixed treatment group have visible liver metastasis of cancer cells, while no obvious liver lesions were found in the ADC (GSH) -MNPs-Gef group.

[0165] Comprehensively considering the therapeutic effects of the above three disease models, the Dual-Nanodrug-System provided by the present invention is based on the amphiphilic polymer PLGA-b-mPEG as the assembly primitive, combined with the method of nanoprecipitation and antibody drug conjugate modification, and a nano delivery system capable of simultaneously loading two different drugs for synergistic treatment of specific diseases is prepared. Through the encapsulation strategy, the Dual-Nanodrug-System shows good biocompatibility and effectively reduces TP toxicity; the Dual-Nanodrug-System has significant kidney targeting, and the kidney retention time is long (7d), which is conducive to improving the utilization rate of the drug, and lays the foundation for its nano drug delivery system for the treatment of different kidney diseases. Compared with the single drug loading system, the dual drug loading platform can further reduce the concentration of drug administration, and reducing the drug administration concentration means the widening of the therapeutic dose window, which also means the rise of treatment safety. In addition, the Dual-Nanodrug-System has extremely strong collocation flexibility, and the two drugs loaded on the platform are flexible, which can meet various synergistic drug use needs, and different drug combinations are loaded in the dual drug loading system. Whether it is the treatment of chronic kidney disease model, acute kidney injury model or renal cancer model, the addition of synergistic drugs has greatly increased the drug dosage compared to single drug carrier. This drug combination can have a good therapeutic effect not only on kidney disease, but also on various primary and secondary diseases of the biological organism.

[0166] The present invention provides a dual-drug-loaded dual-targeted nano drug delivery system (Dual-Nanodrug-System) with the characteristics of simple preparation method, stable loaded drug, clear targeting properties, etc. Through size control, nano-microspheres of various sizes can be prepared very easily, and with different antibodies or aptamers, this targeting carrier can even easily achieve hierarchical targeting of different organs, and is expected to achieve hierarchical targeting and intervention functions of nano-carriers for intracranial vascular lesions, providing a new direction and idea for clinical targeted therapy.

[0167] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A dual-drug-loaded dual-targeted nano drug delivery system, comprising a poly (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer, a nephrin targeting antibody modified on the surface of the copolymer, a hydrophobic drug encapsulated in the (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer, and a hydrophilic drug modified on the surface of the antibody.

2. The dual-drug-loaded dual-targeted nano drug delivery system according to claim 1, characterized in that: The hydrophilic drug is modified on the surface of the nephrin targeting antibody by coupling; and / or, the hydrophobic drug is physically embedded in the (D, L-lactic acid-co-glycolic acid)-methoxypolyethylene glycol amine copolymer; and / or, the nephrin targeting antibody is coupled to the copolymer surface by EDC / NHS chemical reaction.

3. The dual-drug-loaded dual-targeted nano drug delivery system according to claim 1, characterized in that: The poly (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer contains polylactic acid, EDC and methoxy polyethylene glycol amine; preferably, the mass ratio of the polylactic acid, EDC and methoxy polyethylene glycol amine is 8-20:1:2-6.

4. The dual-drug-loaded dual-targeted nano drug delivery system according to claim 3, characterized in that: The preparation method of the poly (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer is as follows: polylactic acid, methoxy polyethylene glycol amine and EDC are dissolved in anhydrous chloroform to carry out amide reaction to obtain the poly (D, L-lactic acid-co-glycolic acid)-methoxy polyethylene glycol amine copolymer.

5. The dual-drug-loaded dual-targeted nano drug delivery system according to any one of claims 1 to 4, characterized in that: The hydrophobic drug is selected from at least one of gefitinib, triptolide and celastrol; the hydrophilic drug is selected from at least one of captopril, captopril acetate, dexamethasone acid and glutathione.

6. The method for preparing the dual-drug-loaded dual-targeted nano drug delivery system according to any one of claims 1 to 5, comprising the following steps: Preparation of hydrophobic drug-MNPs: Mix an acetonitrile solution of a hydrophobic drug with an acetonitrile solution of a poly(D,L-lactic acid-co-glycolic acid)-methoxypolyethylene glycol amine copolymer, and add the mixture dropwise to a poloxamer 188 aqueous solution to react and obtain hydrophobic drug-MNPs; Preparation of hydrophilic drug-Nephrin: activating the reactive groups of hydrophilic drug, Nephrin antibody and GFLG using EDC, NHS and NH2-PEG-NH2 respectively to obtain hydrophilic drug solution, Nephrin antibody solution and GFLG solution; The hydrophilic drug solution is mixed with the GFLG solution, and then mixed with the Nephrin antibody solution after the reaction, and reacted to obtain the hydrophilic drug-Nephrin; Preparation of dual-drug-loaded dual-targeted nano-drug delivery system: Use EDC, NHS and NH2-PEG-NH2 to activate the reactive groups of hydrophobic drug-MNPs, adjust the pH value, and mix and react with the hydrophilic drug-Nephrin to obtain a dual-drug-loaded dual-targeted nano-drug delivery system.

7. The preparation method according to claim 6, characterized in that: In the preparation of the hydrophilic drug-Nephrin, the reaction conditions after the hydrophilic drug solution and the GFLG solution are mixed are oscillating reaction for 10 to 16 hours.

8. The preparation method according to claim 7, characterized in that: The reaction conditions for mixing with the Nephrin antibody solution are as follows: ultrasonication for 8 to 15 minutes followed by stirring for 10 to 16 hours.

9. The preparation method according to claim 6, characterized in that: In the preparation of the dual-drug-loaded and dual-targeted nano drug delivery system, the pH value is adjusted to 6.8-7.2; and or, the reaction condition is room temperature for 2-4 hours.

10. Use of the dual-drug-loaded dual-targeted nano drug delivery system according to any one of claims 1 to 5 in preparing drugs for treating or preventing kidney diseases or in preparing drug delivery systems.